Systemic lupus erythematosus (SLE) is a classic model of a systemic autoimmune disease characterized by the production of antibodies against nuclear antigens and immune-mediated inflammation. Despite therapeutic advances, SLE remains a disease with an unpredictable course, a high risk of irreversible organ damage, and significant mortality at a young age. The paper presents an analysis of current approaches to the early serological and clinical diagnosis of SLE, as well as an assessment of the efficacy and safety of targeted therapies directed at B-lymphocytes and cytokine pathways. A systematic literature review covering the period 2021–2026 incorporating meta-analyses and randomized trials alongside a retrospective analysis of 65 medical records of patients with SLE from a rheumatology department was conducted. It was found that the integration of biomarkers (anti-nucleosome antibodies, anti-C1q) and the new 2019/2022 EULAR/ACR classification criteria into routine practice increased early-stage diagnostic sensitivity to 96%. The efficacy of belimumab and anifrolumab in reducing the SLEDAI-2K score and the cumulative glucocorticoid (GC) dose was demonstrated. Data on the successful use of calcineurin inhibitors (voclosporin) for lupus nephritis (classes III–V) are discussed. Personalized therapy based on immunophenotyping and the assessment of interferon gene signature (IFNGS) activity enables the implementation of a "treat-to-target" strategy in SLE while minimizing steroid exposure.